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Dear editor
Zappacosta et al1 recently published a case report concerning a human papillomavirus 
(HPV)-positive invasive cervical cancer in a 79-year-old women who had a history 
of normal Pap smears. In this article, Anyplex II HPV28 (Seegene) is used for HPV 
genotyping of formalin-fixed paraffin embedded (FFPE) tissue, liquid based cytology 
(LBC) specimens and urine samples. It is suggested that HPV53 is present exclusively 
in the cervical cancer cells, lymph node metastases, and atypical urinary cells of one 
single case while the surrounding CIN2+ tissue revealed ten different HPV strains. 
Unfortunately, the HPV genotype results for lymph nodes and urinary cells are not 
presented while these results underline the potential role of HPV53 in oncogenesis. 
Moreover, it is generally accepted that one lesion is caused by one HPV infection, 
detection of multiple HPV types thus indicates the presence of multiple infections,2 
suggesting that this patient may have several lesions.
In Figure 3 in Zappacosta et al1 two melting peaks (-d(RFU)/dt) for HPV53 are 
displayed, one detected by probe A in plasmid DNA (referred to as a positive internal 
control), and one detected by probe B in cervical cancer cells. However, Anyplex II 
HPV28 only uses one target specific primer/catcher/pitcher set for each HPV type. The 
internal positive control used in Anyplex II HPV28 is human b-globin and not plasmid 
DNA as indicated by Zappacosta et al.1 It is included to monitor whether the sample is 
adequate for analysis and to exclude polymerase chain reaction (PCR)-inhibition which 
may lead to false negative results. The test also includes external positive controls 
which consist of HPV type-specific plasmids, in order to validate whether the prepared 
master mix accurately detects the indicated HPV types. Nevertheless, the authors could 
opt to use synthesized plasmid HPV53 DNA as an extra internal positive control by 
adding it to the sample but this could not be derived from the article. In either case, 
melting curve analysis of the positive control will give a melting profile consisting of 
melting curves specific for each HPV type included in the positive control (personal 
communication Seegene). Because the shape of the melting curve and the position of 
the peak is a signature for each HPV type, infection with a particular HPV type will 
give rise to a particular melting curve. Therefore, it is expected that HPV53 infection 
in cervical cancer cells (right melting curve in Figure 3, Zappacosta et al1) will give 
the exact same melting profile as HPV53 observed in the positive control (left melting 
curve in Figure 3, Zappacosta et al1). This is not the case, as it can be deduced from 
Figure 3, Zappacosta et al. The melting peak of HPV53 in the positive control differs 
approximately 8°C from the HPV type detected in cervical cancer cells.
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The Anyplex II HPV28 is based on melting curve  analysis 
using the TOCE™ technology. In contrast to conventional 
High Resolution Melt (HRM) analysis, the TOCE™ 
 technology enables identification of multiple targets (in 
this case, HPV types) simultaneously in a single channel by 
controlling the catcher melting temperature (catcher-Tm). 
The catcher is an artificial fluorescently labeled template; 
it is designed in such a way that the tagging portion of “the 
pitcher”, which previously recognized and hybridized with 
the target sequence, hybridizes with the catcher. Because each 
HPV-specific pitcher will hybridize with a catcher of a distinc-
tive length causing a temperature shift during the melting out, 
different HPV types will be detected in one single channel 
using one fluorophore. Hereupon, catchers are labeled with 
different fluorophores (FAM, HEX, Cal Red 610, Quasar 670, 
Quasar 705) which are detected using different channels 
allowing multiplexing of 28 different HPV genotypes. 
 Anyplex II HPV28 detects and differentiates 19 high-risk 
(16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 
69, 73, 82) and 9 low-risk HPV genotypes (6, 11, 40, 42, 43, 
44, 54, 61, 70). The kit consists of two independent panels: 
Panel A with 14 high-risks (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68) and Panel B with 5 high-risks (26, 53, 
69, 73, 82) and 9 low-risks HPV.3–5
Zappacosta et al described in their article that urine sam-
ples were analyzed using Hybrid capture II HPV test (HC2 
HPV test).1 To our knowledge, HC2 HPV test has not yet 
been optimized for urine samples.6,7 In-house optimization 
of urine samples for HC2 HPV could have been performed, 
but this is not specified in the article. It is also unclear why 
the authors carried out the HC2 HPV test since the results 
generated by Anyplex II HPV28 and HC2 are not compared 
with each other in the Results section. Moreover, Anyplex II 
HPV28 detects all of the genotypes included in HC2, which 
makes the potential complementary use of HC2 redundant. 
To prevent sample-to-sample contamination, the micro-
tome blade and working space were cleaned with DNA 
Away™ (Thermo Fischer Scientific) after sectioning of each 
FFPE test sample. However, it is unclear whether a negative 
control was included in the experiments in order to exclude 
cross-contamination. Validation for cross-contamination 
could be performed beforehand, but this is not reported in 
the article. A negative control (a tissue that is shown nega-
tive for the tested HPV types) should be cut between the test 
samples ideally after a positive specimen to verify absence 
of cross-contamination. 
In conclusion, based on the observation that the melting 
curve of the HPV type detected in the cervical cancer cells 
does not correspond with the melting curve for HPV53 plas-
mid DNA, it can be deduced that another HPV type might 
be involved in the cervical cancer cells. Hence, it cannot be 
concluded that HPV53 is solely responsible in oncogenesis 
in this case as previously suggested by Zappacosta et al.1
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Lieveld et al listed six weaknesses of our case report. In this 
response we will answer their comments point-by-point.
Firstly, they stated that:
Genotype results for lymph nodes and urinary cells are not 
presented while these results underline the potential role of 
human papillomavirus (HPV)-53 in oncogenesis.
In the “Results” section we wrote:
…the metastatic lymph nodes showed HPV-53; no HPV 
was found in the non-metastatic ones. Atypical keratinizing 
urinary cells also demonstrated a HPV-53 positive result.
Originally, to be concise as per the type of the article 
(case report), we chose to include only one Figure in our 
paper relative to reverse transcription polymerase chain 
reaction (RT-PCR) genotyping results (Figure 3). For the 
reader’s convenience and to further support our findings, 
here we report the modified Figure 3 as a panel of pictures 
including the genotyping results for both lymph nodes and 
atypical urinary cells.
Secondly, referring to our study and in contradiction with 
the previous comment, Lieveld et al also affirmed that:
It is suggested that HPV-53 is present exclusively in the 
cervical cancer cells, lymph node metastasis and atypical 
urinary cells of one single case while the surrounding cer-
vical intraepithelial neoplasia grade 2-or-worse (CIN2+) 
tissue revealed ten different HPV strains.
Within our “Results” section, we clearly stated that “the 
CIN2+ tissue near to the invasive cancer showed HPV-16, 
-35, -39, -40, -53, -54, -59, -61, -68, and -82”. HPV-53 is 
listed among the HPV types which have been found in the 
CIN2+ lesion. On the other hand, HPV-53 alone was detected 
in the cervical cancer cells, lymph node metastasis, and uri-
nary atypical cells. Such finding supports its causative role 
during the last phases of cervical oncogenesis. 
Thirdly, Lieveld et al wrote that:
It is generally accepted that one lesion is caused by one 
HPV infection and detection of multiple HPV types thus 
indicates the presence of multiple infections suggesting that 
this patient may have several lesions.
They also cited Quint et al to support their assertion.2 In 
the “Introduction” section of their paper,2 they clearly confirm 
the well-known theory according to which:
Multiple HPV genotypes are detected in 15%–40% 
of women with prevalent CIN of all grades, and in 60% of 
women with early incident CIN2 and CIN3.
Moreover, they state that “in approximately 95% of HPV-
positive invasive cervical cancers, only one HPV type is 
found”. These assumptions perfectly fit with the concept that 
a single clone of dysplastic cervical would progress toward 
invasive cancer, thus adhering to our findings. 
To confirm the polyclonal nature of the CIN and the 
monoclonal character of the invasive neoplasia, Quint et al 
define high-grade cervical intraepithelial lesions as “archi-
tecturally complex lesions”, which are composed by multiple 
grades of CINs and are “associated with multiple HPV 
infections”. They also conclude that “it is very unlikely that 
multiple HPV types will be present in one HPV-infected cell”. 
To isolate the single area within high-grade CIN, they utilize 
laser capture micro-dissection (LCM). Through HPV PCR 
genotyping performed on LCM-PCR, they demonstrated 
that there is a single HPV type in 93% of the cases, and 
multiple infections in the remaining 7%. Considering such 
results, cervical carcinogenesis would be considered as a con-
tinuum of events, starting from oncogenic HPV infection(s), 
proceeding through intraepithelial neoplasia, and reflecting 
HPV life cycle within the cervical epithelium. At the end of 
this process, the disruption of p53 and pRb mechanisms by 
persistent HPV infection would favor only one dysplastic 
clone, maintained by one single HPV type that would be 
able to switch toward invasive cancer. 
The above mentioned theories are widely accepted 
by the vast majority of the experts in the field and by us. 
Moreover, it is widely accepted that the overall histological 
diagnosis is based on the highest grade of CIN detected, 
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Modified Figure 3 real-time PCr assay performed on tissues (invasive cervical cancer, CIN2+ lesion adjacent to invasive neoplasia, metastatic lymph nodes, non-metastatic 
lymph nodes, and thyroid), and on liquid-based urinary samples.
Notes: Anyplex II HPV28 detection assay simultaneously detects 28 HPV genotypes. β-globin gene is used as a positive internal control to identify processed specimens 
containing substances that may interfere with PCR amplification. Thyroid tissue was used as an external HPV-negative control. (A) Invasive cervical cancer showing positive 
result for HPV-53. (B) CIN2+ lesion, in which positive results for HPVs 16, 35, 39, 40, 53, 54, 59, 61, 68 and 82 have been found. (C) Metastatic lymph nodes, showing HPV-53 
positive result. (D) Non-metastatic lymph nodes, testing as HPV-negative. (E) thyroid tissue testing as HPV-negative. (F) Urinary samples, in which HPV-53 has been found. 
(G) Melting curve of HPV-53 control included in the PC3 mix of set B, demonstrating the melting curve shape and Tm. The melting profile of samples in which HPV-53 has 
been found was shown to have a tm of 76.5°C.
Abbreviations: PCr, polymerase chain reaction; CIN2+, cervical intraepithelial neoplasia grade 2-or-worse; -d(RFU/dT), change in rate of fluorescence units against 
temperature; IC, internal control; PC3 of set B, positive control of set B, consisting of a mix of positive controls, including those of HPVs 73, 53, 70, 6, and 11; tm, melting 
temperature; HPV, human papillomavirus.
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since biopsies might also include areas of lower-grade CIN 
and normal cervical tissue. To perform DNA extraction and 
RT-genotyping of CIN2+ lesions, we isolated the area cor-
responding formalin-fixed paraffin embedded (FFPE) imme-
diately adjacent to the invasive cancer using Tru-Cut biopsy 
needle. The same methods have been used to isolate the area 
showing infiltration of the basal membrane and stroma. In 
this way, we demonstrated multiple concurrent genotypes 
within high-grade CIN (CIN2+), as well as the presence of 
HPV-53 alone within the infiltrating carcinoma (showing 
HPV-53 only). We did not use LCM nor HPV LCM-PCR 
genotyping. Beca et al detected concurrent multiple HPV 
genotypes in about 37% of patients with high-grade cervical 
lesions, and concluded that:
This information might help to better understand the impacts 
of multiple concurrent genotypes infection in the carcinogenic 
process and help to set a baseline measure in future studies on 
the influence of a population-based HPV vaccination.3
Based on this adjunctive information, we confirm that 
our data agrees with previous studies. To further endorse 
our data, we would like to conclude by reporting the find-
ings from Halec et al.4 They demonstrate that when HPV-53 
is presented in cervical cancer cells as a single biologically 
active infection (which is currently considered as a possible 
high-risk oncogenic HPV by World Health Organization), it 
would affect the same cellular pathway as any of the fully-
recognized carcinogenic high-risk types. 
Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1937
A case of HPV-53-related cervical cancer
Fourthly, Lieveld et al illustrated their disagreement 
with our results in Figure 3. We would like to apologize 
since there was a mistake during the editing of this Figure 
and its legend. We made an error when we were including 
curves relative to CIN2+ genotyping rather than to invasive 
neoplasia, and indicating them as belonging to invasive 
cancer tissue. We agree that the internal positive control 
used for Anyplex II HPV28 assay is the human b-globin, 
and that a mixture of pathogen clones are used as external 
positive control (PC) to test the accuracy of master mix in 
detecting the indicated HPV types. Particularly, positive 
control for HPV-53 is included in the PC3 mix of set B. We 
also understand that HPV-53 type specific pitcher hybridized 
with the complementary catcher, the last labeled with HEX 
fluorophore. To avoid any confusion, we would like to make 
it clear that synthesized HPV-53 plasmid was not used as an 
extra internal positive control.
Moreover, we agree that a specific melting profile show-
ing a specific melting temperature (Tm) has to be obtained 
from all samples in which HPV-53 has been found. In this 
context, we would like to thank Lieveld et al for finding this 
error. We have decided to publish a corrigendum, in which we 
included an exhaustive figure-panel representing genotyping 
results as well as the corrected and more detailed legend. As 
shown in the modified Figure 3, the melting profile of each 
sample in which HPV-53 has been detected showed a specific 
melting curve of HPV-53 with a Tm of 76.5°C.
Fifthly, Lieveld et al disagreed that voided urinary 
samples were firstly analyzed by Hybrid Capture II HPV 
test (HC2), since to their knowledge HC2 HPV test had not 
been optimized for urine samples. Numerous studies have 
been performed to optimize HC2 HPV on urine as stated by 
Vorsters et al.5 In this review, Vorsters conclude that “HPV 
detection in urine is a feasible practice and a useful tool in 
future research, but further optimization and standardization 
is required” and that “different settings may require different 
methodologies”.5 It is well known that before introducing a 
new technology into routinely clinical practice, it should be 
evaluated under highly controlled experimental conditions. 
Sellorf et al analyzed vaginal, vulvar and urine samples 
of 200 participants for HPV detection.6 All these specimens 
were sent to Digene Corp. Laboratory (now Qiagen) to 
perform this test. HPVs by HC2 have been detected on 69 
urinary specimens.6 Percentage agreement between cervical 
specimens and urine samples for the presence of HPV was 
found to be 55.2%. Jacobson et al evaluated HPV prevalence 
in both cervical and urine samples among adolescents by 
HC2.7 Brinkman et al detected HPV by HC2 in 28% of urine 
specimens of HIV-positive women.8 Martin-Ezquerra et al 
estimated the incidence of HPV infection in urinary samples 
of 91 male sexual partners of women diagnosed with CIN2-3.9 
They concluded that “HC2 is an easy and economical method 
whose usefulness has been previously demonstrated”.9
In our setting HC2 technology is routinely used to man-
age women reporting low grade squamous intraepithelial 
lesion diagnosis, and during follow-ups after treatment for 
CIN. To evaluate diagnostic performance of HC2 on urinary 
specimens and to contribute to further research in the field, 
this test has to be evaluated in clinical practice. In our paper, 
when we stated that “all the cervical cytological specimens 
resulted as high-risk HPV-positive”, we implied that atypical 
urinary cells were shown to be HC2 negative since HPV-53 
is not included within the 13 oncogenic genotypes included 
in HC2 probe detected by HC2 probe. 
Finally, Lieveld et al asked for additional details 
regarding the laboratory measures employed to prevent 
cross-contamination. In our setting, microtome blade and 
the working space were rinsed with DNA Away™ before we 
handled each tissue block. Before sectioning negative control 
FFPE (human thyroid, previously tested for HPV infection), 
we also changed microtome blade. The melting curve related 
to negative control is shown in Figure 3E. We have omitted 
much of our laboratory measures in our paper as it was a case 
report rather than an original research paper.
In summary, apologizing again for our mistake made in 
the original Figure 3, here we confirm the causative role of 
HPV-53 in the invasive cervical cancer in our patient.
Disclosure
The authors report no conflicts of interest in this work.
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